DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Recommendation of “Moderate Buy” from Brokerages

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $12.3333.

A number of analysts have commented on DMAC shares. Wall Street Zen raised DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Monday, April 20th.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Cooperman Leon G lifted its holdings in DiaMedica Therapeutics by 98.2% in the third quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after acquiring an additional 1,619,761 shares during the period. Millennium Management LLC purchased a new position in DiaMedica Therapeutics in the third quarter worth about $8,157,000. Geode Capital Management LLC grew its stake in shares of DiaMedica Therapeutics by 99.6% during the 2nd quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock valued at $2,458,000 after purchasing an additional 314,407 shares during the period. Royal Bank of Canada grew its stake in shares of DiaMedica Therapeutics by 46,879.1% during the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after purchasing an additional 154,701 shares during the period. Finally, State Street Corp grew its stake in shares of DiaMedica Therapeutics by 31.7% during the 4th quarter. State Street Corp now owns 627,771 shares of the company’s stock valued at $4,997,000 after purchasing an additional 151,188 shares during the period. Hedge funds and other institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Stock Down 2.3%

Shares of DMAC opened at $7.49 on Tuesday. The stock has a market cap of $403.56 million, a P/E ratio of -10.55 and a beta of 0.97. The business’s 50 day moving average price is $6.32 and its 200-day moving average price is $7.14. DiaMedica Therapeutics has a 52 week low of $3.60 and a 52 week high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). On average, equities analysts anticipate that DiaMedica Therapeutics will post -0.86 EPS for the current year.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.